Contact:
Sal Braico at (608)
441-2890
FOR IMMEDIATE RELEASE
July 13, 2004 Madison, WI – ConjuGon, Inc. announced today that it was
awarded a $500,000 Phase II Small Business Innovation Research Grant
from the National Science Foundation (NSF). The grant will help support
the continued development of ConjuGon’s powerful platform technology for
treating and preventing bacterial infections.
“We are pleased that the National Science Foundation recognizes the
magnitude of our work and continues to support it,” said CEO Christopher
Price, who signed on in February as President & CEO.
ConjuGon has raised more than $1.1 million in seed capital, including
$700,000 from angel investors, and $290,000 in economic development
loans from the Madison Development Corporation and the Wisconsin
Department of Commerce. The company was awarded a $100,000 Small
Business Innovation Research (SBIR) Phase I grant from the NSF last
year.
ConjuGon is developing fundamentally new therapeutics to combat the
growing epidemic of antibiotic-resistant bacterial infections.
Antibiotic resistance is a medical crisis, globally responsible for
hundreds of thousands of deaths each year. ConjuGon’s core technology is
a new way to kill unwanted and even multi-drug resistant bacteria.
